NYTimes & Hybrid Medical Media Robert Graham Ph.D. Reporting from Rice University Houston, Texas
What Scientist Taught Was Junk DNA Hybrid Medical Offers Clarity For Breast Cancer Patients
Houston (AP) Hybrid Medical Media received several calls this week asking for clarity on the new DNA finding that the entire science community is paying attention to.
What is in question ENCODE Project’s latest findings,what we as scientist taught was junk DNA contains valuable information. We are happy to Report yes and yes the Encode project has replicated our finding. Gennxeix Biotech has known that with
breast cancer genes is the answer to the cure for breast cancer. We are now able to identify the genes that is associated with breast cancer the breaking news is that there is a regional DNA Regions that regulate the gene like (53, P63,P73). The reason why this is important in breast cancer is, when a breast tumors grows or moves around, is how a patient goes from stage I breast cancer to stage IV.
Brought To You By gloStream
Let's look into the science. A large group of scientists has found that so-called junk DNA, which makes up most of the human genome
, does much more than previously though. Each human cell contains about 10 feet of DNA, coiled into a dense tangle. But only a very small percentage of DNA
encodes genes, which control inherited traits like eye color, blood type and so on.Stretches of DNA around and between genes seemed to do nothing, and were called junk DNA.
But now researchers think that the junk DNA contains a large number of tiny genetic switches, controlling how genes function within the cell. The many genetic regulators seem to be arranged in a complex and redundant hierarchy. Scientists are only beginning to map and understand this network, which regulates how cells, organs and tissues behave.
Errors or mutations in genetic switches can disrupt the network and lead to a range of diseases. The new findings will spur further research and may lead to new breast cancer drugs and treatments .The vast majority (80.4%) of the human genome
participates in at least one biochemical RNA- and/or chromatin-associated event in at least one cell type. Much of the genome lies close to a regulatory event: 95% of the genome lies within 8 kilobases (kb) of a DNA–protein interaction (as assayed by bound ChIP-seq motifs or DNase I footprints), and 99% is within 1.7 kb of at least one of the biochemical events measured by ENCODE.
Primate-specific elements as well as elements without detectable mammalian constraint show, in aggregate, evidence of negative selection; thus, some of them are expected to be functional. Classifying the genome into seven chromatin states
Brought To You By Antiques of River Oaks Houston,Tx indicates an initial set of 399,124 regions with enhancer-like features and 70,292 regions with promoter-like features, as well as hundreds of thousands of quiescent regions. High-resolution analyses further subdivide the genome into thousands of narrow states with distinct functional properties.
It is possible to correlate quantitatively RNA sequence production and processing with both chromatin marks and transcription factor binding at promoters, indicating that promoter functionality can explain most of the variation in RNA expression.
The main difference is that Gennxeix Biotech Rose Conrad says approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma Gennxeix have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2 The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the
processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients. formalin fixed, paraffin embedded techniques and Her-2 Approximately Where do you really come from? And how can this information Solve Breast Cancer? Approximately 30% of malignant breast cancers demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene. HER-2 can be resistant to low-doses of anthracycline-based Hybrid Pharma have demonstrated that they can be used to map DNase (deoxyribonuclease) DNA origins of replication. Hybrid Pharma Recent progress in microarray technology has been related to the development of high resolution microarrays which can map genomic alterations and constitutional variants in DNA copy number at an extremely high resolution for Breast Cancer chemotherapy. formalin fixed, paraffin embedded techniques and Her-2The Good News is that science has advanced. Sections of microarray provide targets for parallel in situ detection of DNA, RNA and protein targets in each specimen on the array. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Hybrid Pharma Semiconductor Sequencing. "Quantum Theory" In Action for Breast Cancer Patients. A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA. RNA template in the processes of replication and transcription. In association with a Hybrid Pharma also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection and Analysis for Breast Cancer model after McCulloch-Pitts. Hybrid Pharma computer-assisted diagnosing of breast cancer from mammograms. Hybrid Pharma works is a genetic network simulation trained with tumor incidence data from knockout experiments. Gennxeix Biotech uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Hybrid's chips are designed like any other semiconductor chips. Pairing proprietary semiconductor technology with sequencing chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released. Gennxeix Biotech used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor. HER2 in many patients respond differently. Genomics can be the GPS to Extend life in Breast Cancer Patients.
No comments:
Post a Comment